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Purpose: To analyze MiRs expression in serum of UM patients, respect to
healthy donors, and to compare this data with MiRs expressed in formalin-fixed,
paraffin-embedded UM samples.
Methods: Expression profile of 754 miRNAs was performed in serum of patients with
uveal melanoma who underwent primary enucleation. The level of miRNAs increased
in serum was individually analyzed on FFPE UM samples and compared to choroidal
melanocytes from unaffected eyes.
Results: Fourteen patients with uveal melanoma were included in the study. We
found 8 serum miRNAs differentially expressed compared to normal controls: 2
upregulated miRNAs (miRNA-146a, miR-523); 6 downregulated miRNAs (miR-19a,
miR-30d, miR-127, miR-451, miR-518f, miR-1274B). When data on upregulated
miRNAs were singularly validated only a significant overexpression of miRNA-146a was
found. A statistically significant upregulation of miRNA-146a was also found on FFPE UM
samples, compared to choroidal melanocytes from unaffected eyes.
Conclusions: miRNA-146a is increased in serum of patients with UM and in FFPE tumor
samples. Further studies will show if it could be considered a potential marker of UM in
the blood.
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INTRODUCTION
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults with an
incidence in the United States of 5.1 cases per million (Singh et al., 2011). It has been estimated
that even with appropriate treatment and close follow-up, 40–50% of patients with UM die from
metastatic disease; the liver is involved in up to 90% of individuals and the median survival is
4–5 months (Kujala et al., 2003). Considering that an early detection could improve the survival
rates of UM, a precise diagnostic test for early melanoma detection could be therefore useful.
The underlying molecular biology of UM is complex and involves interactions between networks
of genes, signaling pathways, and gene regulatory mechanisms, and a better understanding of
these underlying molecular mechanisms is essential for translational research. Most UM cases are
correctly diagnosed through ophthalmoscopy, ultrasonography, fundus fluorescein angiography,
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indocyanine green angiography, and magnetic resonance
imaging (Russo et al., 2015). However, clinical presentation, size
of lesion, opacity of refractive media, intraocular hemorrhage,
and other factors may cause false negative or positive diagnosis.
Effectivemolecular diagnostic markers for this tumor have not
been described. MicroRNAs (miRNAs) are a class of non-coding
small RNAs that regulate gene expression by targeting specific
mRNAs for degradation and/or translational repression and are
involved in a large number of physiological and pathological
processes. A growing body of research has demonstrated
the important role of miRNAs in the initiation, progression,
and metastasis of cancer including melanoma (Lynam-Lennon
et al., 2009; Babashah and Soleimani, 2011; Babashah et al.,
2012; Babashah, 2014). They influence cancer development by
regulating transcription and translation of tumor suppressor
genes and oncogenes. Several miRNAswere discovered in various
body fluids including the serum, plasma, saliva, tears, breast
milk, and urine. Various methods (e.g., qRT-PCR, northern blot,
microarray, and deep sequencing) can be used to detect these
extracellular and secretory miRNAs.
Circulating miRNAs fulfill a number of criteria as ideal
biomarkers: accessibility through non-invasive methods, high
degree of specificity and sensitivity, ability to differentiate
pathologies, long half-life within samples, rapid, and accurate
detection (Chen et al., 2008; Gilad et al., 2008; Mitchell et al.,
2008). Our group previously showed that the expression of
circulating miRNAs in Vitreous Humor (VH) is altered in
different eye pathologies, including UM and in particular that
miRNA-146a was overexpressed more than three-fold in VH
from patients with uveal melanomas (Ragusa et al., 2013, 2015).
Unfortunately, detection of circulating miRNAs in VH for
diagnostic purposes is not currently feasible because vitreous
sampling (i.e., vitrectomy) is an unpleasant and invasive method.
The aim of this work was to analyze MiRs expression in serum
of UM patients, respect to healthy donors, and to compare this
data with MiRs expressed in formalin-fixed, paraffin-embedded
UM samples. This data might suggest the possibility to screen the
blood of uveal melanoma patients and consider a specific miRNA
(146a) as a potential blood marker of UM.
MATERIALS AND METHODS
Patients were included in the study prospectively and
consecutively if they underwent primary enucleation for
choroidal melanoma, at the University of Catania, Italy between
October 2012 and April 2014.
This study was conducted in accordance with
recommendations of the local ethic committee (“Comitato
Etico Catania1”) and the Helsinki Declaration. Before the
procedures written informed consent was obtained from all
research participants in the study.
All patients underwent thorough ophthalmologic evaluations
of the choroidal lesions, including indirect ophthalmoscopy,
standardized A-scan and B-scan echography, fundus fluorescein
angiography, and indocyanine green angiography. Multidetector
computed tomography (MDCT) examination of chest, abdomen
and pelvis was performed in order to assess that no metastatic
disease was present.
Following the diagnosis of UM, eligible patients for
enucleation were selected based on larger basal tumor diameter
and height; as other methods were considered unlikely to
conserve the eye and useful vision without causing excessive
morbidity (Damato and Lecuona, 2004). The serum samples
were collected before the enucleation procedure, which was
performed at the Eye Clinic of the University of Catania.
Parameters considered were: gender, age at diagnosis, location
of the tumor, thickness, largest diameter, cell type, extrascleral
extension, occurrence of metastasis and pathological TNM stage
(Table 1).
Serum Sampling
All enrolled patients underwent fasting venous blood sampling.
We analyzed serum from 14 healthy donors as controls. Blood
samples were obtained by vein puncture using dry vacutainer
tubes (BD Biosciences, Italy). The samples were processed for
serum isolation within 2 h after withdrawal. Whole blood was left
to stand for 30′ at 20◦C before being centrifuged at 3000 rpm for
15′ at 4◦C. Serum was divided into aliquots, and stored at−80◦C
until analysis.
Tumor Samples and Clinico-Pathological
Data
Histological examination was performed at the Unit of
Anatomical Pathology, Department G.F. Ingrassia, University of
Catania, Catania, Italy. Cases of iris melanoma, with incomplete
patient records or without representative tumor tissue in paraffin
blocks, were excluded. Fourteen patients who underwent primary
enucleation were selected for miRNA analysis (Table 1). Controls
for mRNAs in the ocular tissue were choroidal melanocytes from
five unaffected eyes.
RNA Isolation from Serum and miRNAs
Profiling by TaqMan Low Density Array
Serum samples were centrifuged at 2000 rpm for 10′ to pellet
any circulating cell or debris. miRNAs were extracted from
400µl of serum samples by using Qiagen miRNeasy mini
kit (Qiagen, GmbH, Hilden, Germany), according to Qiagen
supplementary protocol for purification of small RNAs from
serum and plasma, and finally eluted in 40µl of elution buffer
(Ragusa et al., 2014). RNAs were quantified by fluorometer
and spectrophotometer. To profile the transcriptome of 754
miRNAs on TaqMan Low Density arrays (TLDA), 30 ng of serum
RNAs were retrotranscribed and pre-amplified, according to the
manufacturer’s instructions. Pre-amplified products were loaded
onto TLDAs, TaqMan Human MicroRNA Array v3.0A and B
(Applied Biosystems|Life TechnologiesTM Monza, Italy). PCRs on
TLDAs were performed on a 7900HT Fast Real Time PCR System
(Applied Biosystem|Life TechnologiesTM Monza, Italy). Results
were validated by single TaqMan assays (Applied Biosystems|Life
TechnologiesTM Monza, Italy) using the same amount of RNAs,
according to the manufacturer’s instructions.
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TABLE 1 | Demographics, tumor parameters, pathological stage in UM patients.
Sex Age Location Thickness (mm) Largest diameter (mm) Cell type Extrascleral extension Metastasis Pathological T stage
F 49 Choroid/cil.body 15.93 19.7 Mixed N N pT4b
M 67 Choroid 16.27 20.8 Spindle N N pT4b
F 54 Choroid/cil.body 11.8 20.1 Mixed N N pT4b
F 67 Choroid/cil.body 15 20 Spindle N N pT4b
F 67 Choroid 14.5 16 Spindle N N pT4a
F 72 Choroid/cil.body 15.5 19.2 Mixed N N pT4b
F 67 Choroid 11 17.5 Mixed N N pT3b
F 59 Choroid 16.9 17 Mixed N N pT4a
M 52 Choroid 15.5 19.3 Spindle N N pT4b
F 29 Choroid 16.4 19.2 Mixed N N pT4a
F 83 Choroid/cil.body 17.8 21.4 Mixed N N pT4a
M 48 Choroid 14.8 19.6 Spindle N N pT4a
F 69 Choroid/cil.body 16.7 20.3 Spindle N N pT4b
M 72 Choroid 14.2 17.6 Mixed N N pT4a
RNA Isolation and RT-PCR from
Formalin-Fixed, Paraffin-Embedded (FFPE)
Samples
For miRNAs extraction, eight sections of 20µm each were cut
from FFPE eyes on a RM2245 microtome (Leica, Bannockburn,
IL, USA). Sections were transferred to glass slides, and tumor
tissue was isolated by hand with a scalpel. We also analyzed FFPE
from five unaffected eyes. RNAs were extracted by using Recover
All Total Nucleic Acid Isolation Kit (Ambion), following the
manufacturer’s protocol. The expression of miRNAs from FFPE
samples was analyzed by TaqManMicroRNAAssay, as previously
specified.
Expression Analysis
To obtain an accurate miRNAs profiling, we used the global
median normalization method (Vallelunga et al., 2014). Based
on this method, we identified most stable miRNA (miR-320)
to be used as reference gene for data normalization of serum
miRNAs in TLDA and single TaqMan assays. For single TaqMan
experiments on FFPE samples snRNA U6 was used as reference
genes, as already reported (Ragusa et al., 2013).
Statistical Analysis
The unpaired T-test was applied to statistically evaluate the
expression differences between patients and healthy controls by
single TaqMan validation assays. A linear correlation analysis was
performed between expression fold changes (FC) of differentially
expressed miRNA in FFPE and serum and tumor diameters.
Statistical significance was established at a p< 0.05.
RESULTS
Clinicopathological Characteristics of
Uveal Melanomas
This study included a total of 14 patients, 10 women and 4 men,
with uveal melanoma. At the time of diagnosis, median age was
61 years (range 29–83 years). The clinicopathological parameters
are listed in Table 1. Of the tumors, 8 (57.1%) were located in the
choroid and 6 (42.9%) tumors involved the choroid and ciliary
body. Histologically, 8 (57.1%) tumors were classified as mixed;
6 (42.9%) as spindle cells. Pathological T stage was pT3b for
1 (7.1%) tumor, 6 (42.9%) was pT4a, 7 (50%) were pT4b. No
liver involvement was detected in all cases. Themedian follow-up
period was 15 months. During the follow-up period, no patients
died due to the disease progression.
Profiling of miRNAs from Serum in UM
Patients
Using TLDA technology, we determined the profiles of 754
miRNAs in serum from 14 patients affected by UM and 14
unaffected controls. Based on SAM analysis (The false discovery
rate <0.05), we found 8 miRNAs differentially expressed
compared to normal controls: 2 upregulated miRNAs (miRNA-
146a, miRNA-523); 6 downregulated miRNAs (miRNA-19a,
miRNA-30d, miRNA-127, miR-451, miR-518f, miR-1274B). We
tested by single TaqMan assays specifically the upregulation
of miRNA-146a and miR-523 because the most interesting as
potential markers of UM. We found that only miRNA-146a was
overexpressed in significantly statistical way in serum of UM
patients respect to normal controls, (p = 0.013; Figure 1). The
linear regression analysis did not show a significant correlation
between tumor size and FC of miRNA-146a (r = 0.146; P =
0.688).
miRNAs Expression in FFPE Uveal
Melanoma Specimens
To verify whether miRNAs alterations observed in serum of
patients with uveal melanoma mirrored some disregulations
originating from tumoral cells, we performed single TaqMan
assays for miRNA-146a on fourteen formalin-fixed, paraffin-
embedded UM samples, and compared them to choroidal
melanocytes from five unaffected eyes. Real Time PCR analysis
showed that miRNA-146a was statistically upregulated in uveal
melanoma cells, as already shown for serum (p < 0.001;
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FIGURE 1 | Single TaqMan assays for miRNA-146a. Box plots
representing the expression of miRNA-146a, analyzed by single TaqMan assay
on serum from an independent cohort of 14 patients and 14 controls. y-axis
represents the −1Ct of miRNAs in melanoma patients respect to normal
controls. Statistical significance was evaluated by the Wilcoxon rank sum test
(p = 0.013).
Figure 2). The linear regression analysis did not show a
significant correlation between tumor size and FC of miRNA-
146a (r = 0.161; P = 0.583).
DISCUSSION
MiRNAs enter into the body fluids with a passive release or an
active secretion. Broken and apoptotic cells can release miRNAs
through passive route (Turchinovich et al., 2012). However,
recent data in the literature reported that cells are also able to
secrete miRNAs with microvescicle-dependent or microvescicle-
free protein dependent pathways. Two types of microvescicle are
secreted from cells: exosomes and shedding vescicle (Simons and
Raposo, 2009). Exosomal microvesicles are secreted by a wide
variety of cell types and can be detected in different body fluids
including the plasma, bronchoalveolar lavage fluid, blood, urine,
bile, ascites, breast milk, and cerebrospinal fluid. The higher
level of stability in many conditions (e.g., repetitive freeze–thaw
cycles, extreme pH, and long-term storage at room temperature)
together with development of sensitive non-invasive detection
methods make miRNAs a potential disease biomarker. However,
some problems remain to be solved. A trustable, approved, and
unique internal to normalize the expression pattern of circulating
miRNAs between case/control patients must be discovered. Low
RNA yield and samples variations can be a problem in next
generation sequencing and microarray profiling.
Considering that cancer cells can transfer miRNAs to the
extracellular environment, several studies have compared the
FIGURE 2 | MiRNAs expression. In FFPE UM specimens. Box plots
representing the expression of miRNA-146a analyzed by single TaqMan assay
on paraffin-embedded UM compared to healthy choroidal melanocytes. y-axis
represents the −1Ct of miRNAs in melanoma patients respect to normal
controls. Statistical significance was evaluated by the Wilcoxon rank sum test
(p < 0.001).
expression profiles of miRNAs in serum or plasma across a
variety of tumors to identify cancer-specific expression patterns.
Recent studies have shown that miRNAs can be measured
in formalin fixed paraffin embedded (FFPE) tissues (Hoshida
et al., 2008). Given the invasive nature of fresh/frozen tissue
collection and the availability of FFPE, this serves as a major
advance in the feasibility of measuring miRNA levels for the
purposes of diagnosis. MiRNA expression profiles have been
used to distinguish tumor from normal samples, identification
of tissue of origin for tumors of unknown origin or in poorly
differentiated tumors and to distinguish different subtypes
of tumors. An ideal cancer biomarker must have a specific
expression profile that distinguish cancer patients from the
normal individuals and must be detect in an early stage of
the disease, before clinical symptoms appear. Data obtained
suggested that circulating miRNAs expression could be used
to discriminate disease samples, demonstrating their potential
use as blood-based diagnostic markers of cancers (Fortunato
et al., 2014; Ganepola et al., 2014; Mar-Aguilar et al., 2014;
Wang et al., 2014). Currently, there are many gaps in our
understanding of the function of cell-secreted miRNAs, and
many biological events these miRNAs are involved in remain
to be elucidated. Two hypotheses are reported in the literature
to explain the role of miRNAs in cancer development. The
first hypothesis highlights the role of miRNAs in regulating
the expression of multiple target mRNAs and therefore control
the state of cellular phenotype. In this way, cancer cells could
benefit from their own specific nich (Hanahan and Weinberg,
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2011). The second hypothesis brings into focus the function
of cf. miRNAs in distant organs. Because of incorporation into
microparticles and exosomes, miRNAs are very stable and can be
measured in the circulation (Ferracin et al., 2010). To develop
sensible and specific blood biomarkers of uveal melanoma
phenotype, we examined levels of circulating miRNAs in patients
with uveal melanoma. By expression profiling we observed a
disregulation of 8 serum miRNAs in UM patients, but after
single assay validations we found as statistically significant only
the overexpression of miRNA-146a. To verify whether miRNAs
alterations observed in serum from melanoma patients were the
result of molecular dysregulations arising from tumoral cells, we
analyzedmiRNA-146a on FFPEUM samples and compared them
to choroidal melanocytes from five unaffected eyes. MiRNA-
146a was statistically upregulated in uveal melanoma cells, as
already shown for serum. Therefore, miRNA-146a was the only
miRNA upregulated both in the serum and FFPE of melanoma
patients suggesting its potential role in neoplastic melanocytes.
Changes in miRNA-146a are observed in human diseases such as
inflammatory disease (Perry et al., 2008) and cancer (Williams
et al., 2008). MiRNA-146a is considered an immune miRNA
with potential immune-suppressive role through its recognized
target genes, IRAK1 and TRAF6. It is a mediator of inflammation
and it is involved in NK cell development and function; its
overexpression in NK cells inhibits proliferation and induces
apoptosis (Sheedy and O’Neill, 2008; Boldin et al., 2011; Paik
et al., 2011). Expression of miRNA-146a is induced by microbial
lipopolysaccharide (LPS), IL-1β and TNF-α with an NF-kappaB
dependent pathway (Taganov et al., 2006). MiRNA-146a has
a role in the complex molecular mechanisms involved in the
control of cell growth, differentiation, and survival, processes
mainly related to cancer development and progression. MiRNA-
146a is overexpressed in papillary thyroid carcinoma (Jazdzewski
et al., 2008), pediatric acute lymphoblastic leukemia and pediatric
acute myeloid leukemia (Zhang et al., 2009), hepatocellular
carcinoma (Xu et al., 2008), and prostate cancer (Xu et al., 2010).
miRNA-146a can suppress the metastatic ability of breast cancer
cells partially through decreasing constitutive NFκB activity
(Bhaumik et al., 2008). Expression of miRNA-146a increases
the ability of human melanoma cells to proliferate in culture
and form tumors in mice (Forloni et al., 2014). Moreover,
miRNA-146a is a target of MITF (Microphthalmia-associated
Transcription Factor), a protooncogenic transcription factor
acting as a master regulator of melanocyte development, function
and survival; it also may be implicated in choroidal melanoma
pigmentation and proliferation (Ozsolak et al., 2008; Chen et al.,
2011; Yajima et al., 2011). Based on these data, miRNA-146a
could have an important regulatory role in the survival of
melanocytes from UM.
Main limit of our study was the relatively small number of
patients included.
Careful examination by experienced clinicians and diagnostic
testing, including angiography, ultrasonography, and magnetic
resonance imaging, can be used to establish and confirm the
diagnosis. Unfortunately often, distinguishing a small UM from
a nevus can be very difficult (Field and Harbour, 2014; Rashid
and Grossniklaus, 2014). Effective molecular diagnostic markers
for this tumor have not been described, yet. In this paper we
demonstrated overexpression of miRNA-146a both in serum
and in FFPE; if tumoral cells are able to secrete miRNA-
146a, this could be detected in VH, as shown in our previous
paper. Unfortunately, detection of circulating miRNAs in VH
for diagnostic purposes is not currently feasible because vitreous
sampling is an unpleasant and invasive method. However, data
shown in this paper suggest the possibility to screen the blood
of uveal melanoma patients to find diagnostic miRNAs released
by the affected eye. Increased miRNA-146a levels could indicate
the neoplastic nature of a lesion, even though further studies will
be needed to statistically validate its diagnostic power on larger
cohorts of patients.
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